Vertex Gears Up For Next Generation In CF Therapy
Orkambi posts sales of $131m in its first quarter on the market, reaching 35% of CF patients eligible for therapy under its label. Firm also updated investors on plans for next-generation CF drugs
Orkambi posts sales of $131m in its first quarter on the market, reaching 35% of CF patients eligible for therapy under its label. Firm also updated investors on plans for next-generation CF drugs